By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AbbVie 



      U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries.


Key Statistics


Email:
Ownership: Public

Web Site: AbbVie
Employees:
Symbol: ABBV
 



Industry
Pharmaceutical






Company News
AbbVie (ABBV) To Present At Goldman Sachs Healthcare CEOs Unscripted Conference 12/24/2014 7:11:21 AM
Gilead Sciences, Inc. (GILD)-AbbVie (ABBV)'s Drug Price War Takes Pharma Back To The Future 12/23/2014 8:52:18 AM
AbbVie (ABBV) Receives Health Canada Approval Of HOLKIRA™ PAK For The Treatment Of Chronic Genotype 1 Hepatitis C 12/23/2014 7:49:07 AM
AbbVie (ABBV)’s Access to Express Scripts Inc. a “Pyrrhic Victory,” Says Analyst 12/22/2014 2:35:33 PM
Enanta Pharmaceuticals, Inc. Announces FDA Approves AbbVie (ABBV)’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) For The Treatment Of Chronic Genotype 1 Hepatitis C Virus 12/22/2014 12:13:55 PM
Express Scripts Inc. Turns to AbbVie (ABBV) In Huge Hepatitis C Deal; Shuns Gilead Sciences, Inc. (GILD) 12/22/2014 6:08:08 AM
AbbVie (ABBV) Receives U.S. FDA Approval Of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) For The Treatment Of Chronic Genotype 1 Hepatitis C 12/22/2014 5:54:40 AM
FDA Approves AbbVie (ABBV)'s All-Oral Hepatitis C Drug Viekira Pak 12/22/2014 5:53:32 AM
Galapagos NV (GLPG.BR) Initiates First Phase 1 Study In Cystic Fibrosis And Will Receive Milestone Payment From AbbVie (ABBV) 12/19/2014 10:33:17 AM
Shire (SHPGY) May Spend AbbVie (ABBV) Breakup Fee On NPS Pharmaceuticals, Inc. (NPSP); NPS Surges On Rumor 12/18/2014 5:52:29 AM
12345678910...
//-->